Several studies reported that the transcription factor NF-κB modulates the transcriptional activity of different target genes, including CD1 and p21Cip/WAF1 [27,28], and that in some in vitro cancer models, OLE reduces the NF-κB expression, leading to the inhibition of tumor cell growth [29,30]. This evidence concerns the gene CDKN1A and cancer.